Latest news

Paper mc4r landscape filter5
Press release | October 1, 2024

Confo Therapeutics Announces Publication in Nature Communications Demonstrating First-Ever Structure of a Complex Between an Antibody-based Agonist and a Class A GPCR Regulating Hunger and Satiety

Cedric quote final launch
Press release | July 26, 2024

Confo Therapeutics Announces EUR 60M Series B Financing to Advance a Pipeline of Novel GPCR-Modulating Therapies into Clinical Development

Confo 07623
Press release | March 28, 2024

Confo Therapeutics Secures VLAIO Grant Supporting Drug Discovery & Development in Endocrine and Metabolic Diseases

Confo 00722
Press release | September 12, 2023

Confo Therapeutics Appoints Stephen Dowd as Chief Business Officer

Confo 00069
Press release | August 29, 2023

Confo Therapeutics Appoints Dieter Weinand, Former CEO of Bayer Pharmaceuticals, as Independent Chairman

Confo 07466
Press release | June 15, 2023

Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera

Confo 06904
Press release | March 30, 2023

Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases

Confo 07427
Press release | March 2, 2023

Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554

2024 jansteyaert fliter5 for launch
Press release | October 28, 2022

Confo Therapeutics’ Scientific Founder Jan Steyaert Receives Prestigious Gabbay Award for Contributions to Structural Biology

Confo 07296
Press release | September 15, 2022

Confo Therapeutics Announces Poster Presentations on CFTX-1554 Preclinical Profiling and Mechanism of Action at the IASP 2022 World Congress on Pain

Confo 06989
Press release | June 28, 2022

Confo Therapeutics Awarded EUR 1.7M VLAIO Grant to Expand Application of ConfoBody® Drug Discovery and Development Technology in Rare Diseases

Confo 07442
Press release | March 10, 2022

Confo Therapeutics Doses First Subjects in Phase 1 Clinical Trial of CFTX-1554 for the Treatment of Neuropathic Pain

Steyaert patent 2025 02 12 154952
Press release | December 15, 2021

Confo Therapeutics Expands Patent Estate for ConfoBody®-based GPCR Screening Platform

Confo 08060
Press release | November 30, 2021

Confo Therapeutics Enters Collaborative Agreement with Regeneron

Confo 08094
Press release | June 10, 2021

Confo Therapeutics Establishes Medical Advisory Board

Confo 01458
Press release | March 30, 2021

Confo Therapeutics Awarded EUR 1M VLAIO Grant for Pre-Clinical Development of CFTX-1554, an AT2R Modulator for the Treatment of Neuropathic Pain

Confo 07999
Press release | October 15, 2020

Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development

Confo 00670
Press release | June 10, 2020

Confo Therapeutics Expands Board with Appointment of Rob Scott as Independent Director

Confo 05101
Press release | June 3, 2020

Confo Therapeutics Appoints Paolo Vicini as Chief Development Officer

Rectangle 6823@4x
Press release | February 27, 2020

Confo Therapeutics to present at Cowen 40th Annual Health Care Conference

Steyaert patent 2025 02 12 154952
Press release | December 2, 2019

Confo Therapeutics reports grant of two key patents for ConfoBodies™

Fierce 15 2016
Press release | September 23, 2019

FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 2019

Confo 06826
Press release | July 3, 2019

Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds

Confo 06893
Press release | June 20, 2019

Confo Therapeutics receives €1.7 million grant from VLAIO to progress novel GPCR-modulating compounds for an orphan indication

Cedric quote final launch
Press release | May 7, 2019

Confo Therapeutics raises €30 million in Series A financing

Confo 07875
Press release | February 28, 2019

Confo Therapeutics forms Scientific Advisory Board as it accelerates development of proprietary drug discovery engine

Confo 07463
Press release | January 3, 2019

Confo Therapeutics Announces Exclusive, Worldwide License Agreement with VIB for Powerful Novel Structure Determination Technology

Confo 00326
Press release | December 7, 2018

Confo Therapeutics Appoints Frank Landolt as its Chief Counsel Legal & Intellectual Property

Confo 06862
Press release | February 20, 2018

Confo Therapeutics is awarded a EUR 1M grant to increase its screening capabilities

Confo 07655
Press release | December 19, 2017

Confo Therapeutics enters into drug discovery collaboration with Roche

Confo 07660
Press release | September 26, 2017

Confo Therapeutics enters into drug discovery collaboration with Lundbeck

Confo 06786
Press release | February 1, 2017

Confo Therapeutics is awarded EUR 2.6M in non-dilutive funding for the discovery of new fibrosis treatments and for expanding the use of its unique Confo® technology

Rectangle 21@4x
Press release | December 15, 2016

Confo Therapeutics to appoint John Berriman as Chairman of the Board

Confo 05121 cedric crop
Press release | September 7, 2016

Confo Therapeutics appoints Dr. Cedric Ververken as Chief Executive Officer

Confo 05348
Press release | May 10, 2016

Confo Therapeutics appoints Dr Christel Menet as Chief Scientific Officer

Confo 07382
Press release | February 2, 2016

Confo Therapeutics secures €6.7 million in first financing round